Lancet Infect Dis. 2019 May;19(5):e179-e186. doi: 10.1016/S1473-3099(18)30646-7. Epub 2018 Nov 28.
The resurgence and changing epidemiology of pertussis in high-income countries, the high infant mortality caused by pertussis in low-income countries, and the increasing morbidity in all age groups worldwide call for a concerted effort to both improve the current vaccines and develop new vaccines and vaccination strategies against pertussis. In this Personal View, we identify several key obstacles on the path to developing a durable solution for global control of pertussis. To systematically address these obstacles, the PERtussIS Correlates Of Protection Europe (PERISCOPE) Consortium was established in March, 2016. The objectives of this consortium are to increase scientific understanding of immunity to pertussis in humans induced by vaccines and infections, to identify biomarkers of protective immunity, and to generate technologies and infrastructure for the future development of improved pertussis vaccines. By working towards the accelerated licensure and implementation of novel, well tolerated, and effective pertussis vaccines, we hope to strengthen and stimulate further collaboration and transparency between the key stakeholders, including the public, the scientific community, public health institutes, regulatory authorities, and vaccine manufacturers.
高收入国家百日咳的死灰复燃和流行情况的变化，低收入国家百日咳导致的高婴儿死亡率，以及全球所有年龄组发病率的增加，都呼吁我们共同努力，既要改进现有的疫苗，又要开发针对百日咳的新疫苗和新接种策略。在这篇个人观点文章中，我们确定了在为全球百日咳控制开发持久解决方案的道路上存在的几个关键障碍。为了系统地解决这些障碍，PERtussIS Correlates Of Protection Europe（PERISCOPE）联盟于 2016 年 3 月成立。该联盟的目标是增加对疫苗和感染引起的人类百日咳免疫力的科学认识，确定保护性免疫的生物标志物，并为未来改进的百日咳疫苗的开发提供技术和基础设施。通过努力加速新型、耐受性好和有效的百日咳疫苗的许可和实施，我们希望加强和进一步刺激包括公众、科学界、公共卫生机构、监管机构和疫苗制造商在内的主要利益攸关方之间的合作和透明度。
